Registration for this event is now closed due to reaching a full capacity. We are not holding a waiting list.

The UK has been an innovation and regulatory leader in the cell and gene therapy field since the emergence as an exciting new therapeutic modality began to gain momentum over the past 15 years or more. The UK, through public and private sector investment continues to be a leading location for innovation in the field although competition is never far away. This event will see presentations on the current landscape of the Cell & Gene Therapy development in the UK followed by a panel discussion exploring what the UK needs to do in order to remain a leading player in the space.

Agenda:
17.30  Registration and networking
18.00  Welcome from One Nucleus
18.05  Overview of Cell & Gene Therapy in the UK
Lee Dunham, Director of Business Development, Cell & Gene Therapy Catapult
18.25  Plurify: A Case Study
          Djordje Djordjevic, CEO & Co-founder, Plurify
18.50  Panel Discussion: How Will the UK Remain a Location of Choice for Cell & Gene Therapy Investment?
Claire Smith, Partner, Bristows (moderator)
Djordje Djordjevic, CEO & Co-founder, Plurify
Lee Dunham, Director of Business Development, Cell & Gene Therapy Catapult
Chris Baker, Investment Principal, LifeArc Ventures
Hiroyuki Usuda, Scouting & Transaction lead, Business Development, Astellas Pharma Europe
19.35  Closing Remarks
19.40  Networking over drinks and canapes
21.00  Close

Prices:
Members: Free
Non-members: £50 +VAT
Academics: please contact info@onenucleus.com